Press Releases

After the release of the World Health Organization Pandemic Accord negotiating draft, BIO's Senior Vice President of Infectious Disease & Emerging Science Policy, Phyllis Arthur, made the following remarks: “The Biotechnology Innovation…

The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning…

Today, the Biotechnology Innovation Organization (BIO) awarded Indiana Governor Eric Holcomb with its 2023 Governor of the Year Award. Throughout his tenure, Governor Holcomb has worked to support the promise of future bioscientific innovation and…

Updated regulatory working groups announced today by the Biotechnology Innovation Organization (BIO) reflect the rapidly increasing diversity and impact of BIO’s Agriculture & Environment membership and ensure that all member companies’…

Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks: "This legislation is a welcome…

The Biotechnology Innovation Organization has honored two biotechnology leaders who are driving cutting-edge breakthroughs in agricultural, environmental and industrial biotechnology. Dr. Pam Marrone, Co-founder and Executive Chair of Invasive…

Yesterday the Federal Trade Commission (FTC) announced the decision to settle its Amgen-Horizon merger challenge. The settlement will give the Commission the relief it needs to protect competition, while allowing rare disease patients to enjoy the…

New Season of I am BIO Podcast Covers Birds, Bees, and Bugs Fall 2023 season explores biotech solutions for wildlife conservation, bee health, drug-resistant bugs, and more Washington – (Aug. 30, 2023) – Save the date―the Biotechnology Innovation…

The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price…

BIO released the following statement from John Delacourt, BIO’s Deputy General Counsel, on BIO’s amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen: “The FTC’s current overreach in…